Novel mechanisms and treatment of idiopathic pulmonary fibrosis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease of unknown etiology that carries a grim prognosis. Over the last few decades there have been significant advances in our understanding of the mechanisms that drive the fibrotic process. In this review, we discuss the natural history of IPF, recent discoveries of the genetic factors and environmental and infectious exposures that influence the development and progression of the disease, and highlight some of the novel discoveries in our understanding of the mechanisms that govern lung fibrosis. Finally, we discuss the new and exciting therapies that are now available to manage this devastating illness.

Original languageEnglish (US)
Pages (from-to)145-153
Number of pages9
JournalDiscovery medicine
Volume20
Issue number109
StatePublished - Jan 1 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Environmental Exposure
Disease Progression
Fibrosis
Lung
Therapeutics

Cite this

Novel mechanisms and treatment of idiopathic pulmonary fibrosis. / Elmufdi, Firas; Henke, Craig A; Perlman, David M; Tomic, Rade; Kim, Hyun J.

In: Discovery medicine, Vol. 20, No. 109, 01.01.2015, p. 145-153.

Research output: Contribution to journalArticle

@article{f8c5fca101cf4f099b811d2cec7cdb4d,
title = "Novel mechanisms and treatment of idiopathic pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease of unknown etiology that carries a grim prognosis. Over the last few decades there have been significant advances in our understanding of the mechanisms that drive the fibrotic process. In this review, we discuss the natural history of IPF, recent discoveries of the genetic factors and environmental and infectious exposures that influence the development and progression of the disease, and highlight some of the novel discoveries in our understanding of the mechanisms that govern lung fibrosis. Finally, we discuss the new and exciting therapies that are now available to manage this devastating illness.",
author = "Firas Elmufdi and Henke, {Craig A} and Perlman, {David M} and Rade Tomic and Kim, {Hyun J}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "20",
pages = "145--153",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "109",

}

TY - JOUR

T1 - Novel mechanisms and treatment of idiopathic pulmonary fibrosis

AU - Elmufdi, Firas

AU - Henke, Craig A

AU - Perlman, David M

AU - Tomic, Rade

AU - Kim, Hyun J

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease of unknown etiology that carries a grim prognosis. Over the last few decades there have been significant advances in our understanding of the mechanisms that drive the fibrotic process. In this review, we discuss the natural history of IPF, recent discoveries of the genetic factors and environmental and infectious exposures that influence the development and progression of the disease, and highlight some of the novel discoveries in our understanding of the mechanisms that govern lung fibrosis. Finally, we discuss the new and exciting therapies that are now available to manage this devastating illness.

AB - Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease of unknown etiology that carries a grim prognosis. Over the last few decades there have been significant advances in our understanding of the mechanisms that drive the fibrotic process. In this review, we discuss the natural history of IPF, recent discoveries of the genetic factors and environmental and infectious exposures that influence the development and progression of the disease, and highlight some of the novel discoveries in our understanding of the mechanisms that govern lung fibrosis. Finally, we discuss the new and exciting therapies that are now available to manage this devastating illness.

UR - http://www.scopus.com/inward/record.url?scp=84944452839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944452839&partnerID=8YFLogxK

M3 - Article

C2 - 26463096

AN - SCOPUS:84944452839

VL - 20

SP - 145

EP - 153

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 109

ER -